Hepatitis C desease

There is some evidence that if the test is “weakly positive,” it may be a false positive The Centers for Disease Control and Prevention (CDC) recommends that all positive antibody tests be followed by an HCV RNA test that detects viral RNA in the blood to determine whether or not the person has an active infection. A test is now available to identify antibody (proteins produced by the immune system in response to the virus) to HCV, which is present in approximately 50 percent of persons with early hepatitis C infections and in almost all with chronic hepatitis C infections. Use with or without ribavirin for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis.

images

Treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients (18 years of age and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy. Treatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease who have a history of blood or blood-product exposure and/or are HCV antibody positive. Treatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease who have anti-HCV serum antibodies and/or HCV RNA.

A fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection -without cirrhosis or with compensated cirrhosis or with decompensated cirrhosis for use in combination with ribavirin. People who are infected with hepatitis C should seek advice about minimising further damage to their liver from alcohol and drug use , and preventing co-infection with blood borne viruses, including immunisation against hepatitis A and hepatitis B. It is believed without treatment, 25% of people with chronic hepatitis C will develop cirrhosis over an average period of 18 years and will have a higher risk of developing liver cancer over the next decade.

Even without symptoms, though, people with chronic hepatitis C are at risk for serious liver diseases such as cancer, cirrhosis (scarring of the liver), or liver failure, all of which can be fatal (but may not show signs for years). As a result, after diagnosing hepatitis C, healthcare providers often do follow-up tests for HIV, and hepatitis A and B. People whose tests show they are not immune to hepatitis A and B should get vaccinated against these infections. Hepatitis B and Hepatitis C can also begin as acute infections, but in some people, the virus remains in the body, resulting in chronic disease and long-term liver problems.

In April 2016, WHO updated its “Guidelines for the screening, care and treatment of persons with chronic hepatitis C”. These guidelines complement existing WHO guidance on the prevention of transmission of bloodborne viruses, including HCV.
baca juga :
cara mengobati difteri
obat kista bartholin
cara mengobati katarak
cara mengobati gondok
cara mengobati hepatitis c
cara menyembuhkan asam urat

Leave a Reply